1Zhang)(J,Zhang AP,Yang S,et a1.Association of HLA class I alleles with Psoriasis vulgaris in southeastem Chinese Hans[J].J Demratol Sei,2003,33(1):l-6.
2Ouyang W,Kolls JK,Zheng Y.The biological functions of T helper 17 cell effector cytokines in inflammation[J].Immunity,2008,28(4):454-467.
4Krueger GG,Papp KA,Stough DB,et al.A randomized,doubleblind,placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis[J].J Am Acad Dermatol,2002,47(6):821-833.
二级参考文献21
1Greaves MW, Weinstein GD. Treatment of Psoriasis[J]. N Engl J Med, 1995, 332 (9) :581 -589.
2Griffiths CE. The immunological basis of psoriasis[J]. J Eur Acad Dermatol Venereol, 2003,17(Suppl 2) :1 -5.
3Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons leaned, unresolved issues and future directions[ J]. Curr Dir Autoimmun, 2010, 11 : 180 -210.
4Austin LM, Ozawa M, Kikuchi T, et al. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TI-II ellector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients [ J ]. The Journal of investigative dermatology, 1999,113 ( 5 ) : 752 -759.
5Di Cesare A ,Di Meglio P,Nestle FO. The IL- 23/Th17 axis in the immunopathogenesis of psoriasis [ J ]. J Invest Dermatol, 2009, 129 (6) :1339 - 1350.
6Panayi GS. hnmunology of psoriasis and psorlatic arthritis [J]. Baillieres Clin Rheumato1,1994,8 (2) :419 -427.
7Lebwohl M, Christophers E, Langley R, et al. A international, randomized, double- blind, placebo-controlled phase 3 trial of in- tramuscular alefaeept in patients with chron- ic plaque psoriasis [J]. Arch Dermatol, 2003,139(6) :719 - 727.
8Kmeger GG, Papp KA, Stough DB,et al. A randomized, double-blind, placebo-con- trolled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis [ J ]. J Am Acad Demmtol, 2002,47 ( 6 ) : 821 - 833.
9Goffe B, Papp K, Gratton D,et al. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy [J]. Clin Ther, 2005, 27 (12) :1912 -1921.
10Leonardi C, Menter A, Hamilton T,et al. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis [ J ]. Br J Dermatol, 2008, 158 (5) :1107 -1116.
